Xcellerex
美國Xcellerex www.xcellerex.com
總部位于馬薩諸塞州的Xcellerex擁有135名雇員，其營收大約為5000萬美元。該公司獲得的風險資本投資包括Kleiner Perkins Caufield & Byers、VantagePoint Venture Partners和SCG Capital。
2012年GE Healthcare收購Xcellerex
Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized.
Xcellerex is built around a unique biomanufacturing platform that features the innovative application of single-use component technology. The Xcellerex platform transforms biomanufacturing economics by enabling:
Faster deployment of new manufacturing capacity: 12-18 months vs. 3-5 years.
Reduced capital investment: Typical savings of 50% to 70% compared to conventional approaches.
Unmatched flexibility: Modular microenvironment approach enables fast, low-cost redeployment for multi-drug production.
Xcellerex offers a suite of world-class products and services to support the adoption of its platform. These include the XDR line of single-use bioreactors, PDMax® high-throughput process development and optimization services, and proven GMP manufacturing operated by an experienced CMC team. The company also actively seeks creative partnerships to facilitate access to the platform.
